



**STUDY OF MICROALBUMINURIA AND SERUM CREATININE IN HYPERTENSIVE PATIENTS AS EARLY INDICATOR FOR RENAL DISEASES**

**Sanjay Kumar Deshwali\*, Mohammad Arshad and Fahad Mohammad Alruwais**

<sup>1</sup>Department of Basic Sciences, College of Medicine Aldawadmi, Shaqra University, Kingdom of Saudi Arabia.

**Corresponding Author:** Sanjay Kumar Deshwali

Department of Basic Sciences, College of Medicine Aldawadmi, Shaqra University, Kingdom of Saudi Arabia.

**Article Received on 20/01/2018**

**Article Revised on 10/02/2018**

**Article Accepted on 02/03/2018**

**ABSTRACT**

**Introduction:** Renal damage occurs in maximum case of hypertension. It may be 100% prevalent when duration is more than 10 yrs and gets accelerated when there is simultaneous presence of other metabolic syndromes like DM-2, insulin resistance and obesity. If Kidney damage is detected in early stage with progression to end stage of renal disease drug treatment can be decided. **Methodology:** The Blood and Urine sample of 50 hypertensive patients with HTN were collected from OPD, Dawadmi Hospital and Health Centers, Dawadmi KSA for determination of serum creatinine and ACR respectively. **Result:** Hypertensive patients as having more than normal serum creatinine level have high value of UACR thus we can say that increment in serum creatinine level is advance stage of renal damage. **Conclusion:** The study concludes that hypertensive patients are more prone to renal damage which can be efficiently diagnosed by microalbuminuria than serum creatinine assessment which is extensively used in other countries and can be used frequently for the better management of the Renal diseases.

**KEYWORDS:** Microalbuminuria, Creatinine, hypertensive and renal diseases.

**1. INTRODUCTION**

Hypertension (HTN) also known as high blood pressure, is a long term medical condition in which the blood pressure in the arteries is persistently elevated. High blood pressure may increase the risk of heart, kidney and eye disorders.<sup>[1,2]</sup> HTN is a major public health problem in the worldwide. The incidence of hypertension in Saudi Arabia is 5-15% in adult population against 10-12% in European countries.<sup>[3,4]</sup> Renal dysfunction occurs in most of hypertensive cases.<sup>[4,5]</sup> It may be 100% prevalent when duration is more than 10 yrs and gets accelerated when there is simultaneous presence of other metabolic syndromes like Type 2 DM, Insulin resistance and obesity.<sup>[6, 7]</sup> Detection of kidney damage in early stage can prevent the progression to end stage of renal disease and helpful to choice of treatment.<sup>[8]</sup> Renal failure is a condition where kidney loses their normal functioning and is characterized by the reduction in the excretory and regulatory functions of kidneys.<sup>[9]</sup> Renal damage may be assessed by imaging techniques, substance accumulation, clearance techniques, urine analysis, and microalbumin quantification. Among these substance accumulation and microalbumin quantification are the easy and feasible markers of early renal damage which indicates the presence of proteinuria.<sup>[8, 9]</sup> An abnormally high amount of albumin excretion in urine is an important risk factor for identifying kidney disease.<sup>[10]</sup> Microalbuminuria is prevalent in 25-100% patients with hypertension.<sup>[1, 11, 12, 13]</sup> Creatinine has also found to be fairly reliable indicator of kidney function, any impairment in kidney function

will result in rise of blood creatinine level due to poor clearance by the kidneys.<sup>[14]</sup> In present scenario substance accumulation is used as a routine procedure while microalbuminuria is an independent predictor of mortality in patients with essential Hypertension.<sup>[15, 16, 17]</sup> This is strongly correlated with severity and duration of Hypertension.<sup>[18]</sup> Screening of microalbuminuria requires either collection of 24 hrs urine or determination of albumin/creatinine ratio in spot urine sample. It is found that albumin/creatinine ratio didn't provide any advantage compared with microalbumin measurement alone.<sup>[19]</sup> The measurement of blood creatinine, and proteinuria are relatively insensitive and show abnormalities when the disease process is advanced. Very few studies previously reported on hypertension in KSA. The most recent estimates date back to 2005 and provided a prevalence of 11.5% of reportedly diagnosed hypertension, among individuals aged 15–64 years, a much higher prevalence than 5.6% from our study. Data from 1995–2000 for Saudis aged 30 years or older showed a hypertension prevalence of 26.1%. In comparison, we found that 27.2% of those aged 30 or older had hypertension. There are several factors that could explain these differences. First, our study is national and applied standardized methodology for data collection. Second, we used weighted analyses to generalize our findings. However, the 2005 STEPS survey and our study should be comparable and possibly indicate a leveling of the hypertension prevalence in KSA.<sup>[6,3]</sup> The aim of present study is assessing the

relative importance of microalbuminuria and substance accumulation to understand whether it should be used as a routine procedure in evaluation of renal damage in hypertension in Saudi Arabian Population.

## 2. MATERIAL AND METHODS

The present study is a case control study conducted in Dawadmi, College of Medicine, Dawadmi KSA. The study comprises of 50 hypertensive subjects as study cases and age sex matched healthy controls. The Blood and Urine sample of 50 hypertensive patients with HTN were collected from OPD, Dawadmi Hospital and Health Centres, Dawadmi KSA for determination of serum creatinine and ACR respectively.

### COLLECTION OF SAMPLE

2 ml of blood sample was collected in sterile vials and centrifuge for separating serum.

### PRESERVATION OF SAMPLE

#### REACTION



#### MATERIALS PROVIDED

Reagent 1- Picric acid

Reagent 2- 0.75 NaOH

Reagent 3- Stock Creatinine (150 mg/ dl)

To prepare working standard 0.1 ml reagent 3 was diluted with 10 ml of distilled water.

Separated serum was preserved in refrigerator at 2-8°C until analysis.

#### PARAMETERS ESTIMATED

Serum Creatinine.

Urine Creatinine

Urine Microalbumin.

UACR

#### ESTIMATION OF SERUM CREATININE

Serum creatinine was estimated by alkanine picrate method of Jaffee (1977).

#### PRINCIPLE

Protein free solution of creatinine was obtained by precipitating step reacts with picric acid in alkaline medium to form an orange coloured complex, The Intensity of which is proportional to the amount of creatinine present in the sample and it is measured colorimetrically at 520 nm or with green filter.

#### PROCEDURE

For De-Proteinisation.

Serum	1.0ml
Distilled water	1.0ml
Reagent 1	6.0ml

Mix well, keep in boiling water bath for 60 sec, cool under running tap water, centrifuge and filter.

#### FOR ESTIMATION

	Blank	Test	Standard
Filterate/ Supernatant	-	4.0ml	-
Working Standard	-	-	1.0ml
Distilled Water	1.0ml	-	-
Reagent 1	3.0ml	-	3.0ml
Reagent 2	1.0ml	1.0ml	1.0ml

Mix well and allow standing at room temperature for 20 min. Measure the absorbance of Blank, Test, Standard against distilled water, at 520 nm or green filter.

#### CALCULATION

$$\text{Serum Creatinine in mg \%} = \frac{\text{AT-AB} \times 3.0}{\text{AS-AB}}$$

#### ESTIMATION OF URINE CREATININE

Urine Creatinine was estimated by alkanine picrate method of Jaffee (1977).

#### REACTION



#### MATERIALS PROVIDED

Reagent 1- Picric acid

Reagent 2- 0.75 NaOH

Reagent 3- Stock creatinine (150mg/dl)

To prepare working standard 0.1 ml reagent 3 was diluted with 10 ml of distilled water.

#### PRINCIPLE

Protein free solution of creatinine obtained by precipitating step reacts with picric acid in alkaline medium to form an orange coloured complex, The Intensity of which is proportional to the amount of creatinine present in the sample and it is measured colorimetrically at 520nm or with green filter.

#### PROCEDURE

For De-Proteinisation-

Diluted urine	1.0ml
Distilled water	1.0ml
Reagent 1	6.0ml

Mix well, keep in boiling water bath for 60 sec, cool under running tap water and centrifuge/filter.

#### FOR ESTIMATION

	Blank	Test	Standard
<b>Filterate/ Supernatant</b>	-	4.0ml	-
<b>Working standard</b>	-	-	1.0ml
<b>Distilled water</b>	1.0ml	-	-
<b>Reagent 1</b>	3.0ml	-	3.0ml
<b>Reagent 2</b>	1.0ml	1.0ml	1.0ml

Mix well and allow standing at room temperature for 20 min. measure the absorbance of Blank, Test, Standard against distilled water, at 520 nm or green filter.

#### CALCULATION

$$\text{Urine creatinine in mg/litre} = \frac{\text{AT-AB} \times 0.75}{\text{AS-AB}}$$

#### ESTIMATION OF URINE MICROALBUMIN

It was estimated by Turbidimetric immunoassay based on agglutination reaction (1976).

#### PRINCIPLE

It is a turbidimetric assay for the detection of albumin in urine and is based on principle of agglutination reaction. The test specimen is mixed with the Activation Buffer (R1) and Anti Human Ab Solution (R2) and is allowed to react. Presence of albumin in the test specimen forms a turbidity, which is measured at wavelength 546 nm. The resulting turbidity corresponds to the concentration of albumin in the test specimen.

#### CALCULATIONS

$$\text{Concentration of Microalbumin in g/l} =$$

$$\triangle A = A_2 - A_1$$

#### MATERIALS PROVIDED

R1- Activation Buffer  
R2-v Anti Human Albumin  
R3- Calibrator (100mg/dl)

#### PROCEDURE

Wavelength-546nm  
Reaction temperature-37°C.

#### Cuvette- 1 cm path length

	For Calibration	For Sample
<b>R1</b>	450µL	450 µL
<b>R2</b>	50 µL	50 µL

#### Mix well and incubate for 5 min

<b>R3</b>	10 µL	-
<b>Sample</b>	-	10 µL

Mix well and read absorbance at 10 sec (A1) and at 2 min(A2).


$$\frac{\triangle A \text{ Sample}}{A} \times \text{Conc. of Calibrator}$$

$$\text{UACR in mg/g} = \frac{\text{Urine Albumin (mg/dl)}}{\text{Urine Creatinine (g/dl)}}$$


#### 3. OBSERVATIONS

Table- 1: Distribution of Hypertensive Patients According to Duration of Htn And Age.

DISTRIBUTION OF HYPERTENSIVE PATIENTS					
ACCORDING TO DURATION OF HTN			ACCORDING TO AGE		
Duration of HTN	Number	Percentage	Age	Number	Percentage
<4	23	46	<30	4	08
4-8	17	34	30-40	4	08
8-12	6	12	40-50	14	28
12-16	2	04	50-60	9	18
>16	2	04	60-70	13	26
-	-	-	>70	6	12



**Figure-1:** Maximum frequency of Hypertension patient fund with duration of less then 4 years.



**Figure-2:** Maximum hypertensive patients belongs to age group 40-50 yrs.

**Table-2: Distribution of Hypertensive Patients According to Serum Creatinine, Urine Creatinine and Urine Albumin.**

Distribution Of Hypertensive Patients								
According To Serum Creatinine			According To Urine Creatinine			According To Urine Albumin		
Serum Creatinine	Number	Percentage	Urine creatinine	Number	Percentage	Urine albumin		
<.40	2	04	<.30	3	06	<40	40	80
<b>0.40-0.80</b>	14	28	<b>.30-.60</b>	12	24	<b>40-80</b>	3	06
<b>0.80-1.20</b>	24	48	<b>.60-.90</b>	28	56	<b>80-120</b>	5	10
<b>&gt;1.20</b>	10	20	<b>.90-1.20</b>	6	12	<b>120-160</b>	1	02
-	-	-	<b>&gt;1.20</b>	1	02	<b>&gt;160</b>	1	02




Figure-3: Maximum hypertensive patients have serum creatinine value 0.80-1.20 mg/dl.




Figure-4: Maximum hypertensive patients have urine creatinine value in the range 0.60-0.90 g/ dl.





Figure-5: Maximum hypertensive patients have urine albumin <40 mg/ dl.

**Table -3: Distribution Of Hypertensive Patients According To Type Of Hypertension**

Stage of HTN	Hypertensive Patients		
	Male (In %)	Female In (%)	Total(%)
I	54	46	50
II	46	54	50

**Figure-6: Type I and type II hypertension is equally prevalent among hypertensive patients, with proportion to 54:46 in male and 46:54 in female.****Table – 4: Correlation of Serum Creatinine, Urine Albumin and Uacr with Age, Duration of Htn and Type of Hypertension.**

CORRELATION OF SERUM CREATININE, URINE ALBUMIN AND UACR WITH AGE			
Age	Mean Serum Creatinine	Mean Urine Alb	Mean UACR
<30	0.9425	22.7775	28.225
30-40	0.76	52.8	72.1075
40-50	0.9836	14.4864	23.10286
50-60	0.9478	39.871111	58.34556
60-70	0.8931	36.166	55.18294
>70	0.9567	43.84833	65.97833
CORRELATION OF SERUM CREATININE, URINE ALBUMIN AND UACR WITH DURATION OF HTN			
Duration of HTN	Mean Serum Creatinine	Mean Urine Alb.	Mean UACR
<4	0.8158	20.57	30.02654
4-8	0.9379	15.416	22.79
8-12	1.1714	60.13833	83.22167
12-16	1.245	95	115.1
>16	1.345	147.865	230.4
CORRELATION OF SERUM CREATININE, URINE ALBUMIN AND UACR WITH TYPE OF HYPERTENSION			
Stage of HTN	Mean Serum Creatinine	Mean Urine Alb.	Mean ACR
I	1.018	36.66	53.568
II	0.8456	27.228	38.039




Figure-7: Serum creatinine urine albumin and UACR shows no correlation with age.




Figure-8: Serum Creatinine, Urine Albumin and UACR is increasing with Duration of HTN shows positive correlation with duration of HTN.






Figure-9: Serum Creatinine, urine albumin and UACR is found to be high in type I than in type II HTN.

**Table – 5: Prevalence of Microalbuminuria In Hypertensive Patients, Duration of Htn, Age And Sex Ratio.**

PREVALENCE OF MICROALBUMINURIA IN HYPERTENSIVE PATIENTS		
UACR	Frequency	Percentage
<30	36	72
30-300	14	28
PREVALENT DURATOIN OF HYPERTENSION IN HYPERTENSIVE PATIENTS MANIFESTED WITH MICROALBUMINURIA		
UACR	DURATION OF HTN	
<30	3.0416	
30-300	10.0178	
PREVALENT AGE IN HYPERTENSIVE PATIENTS MANIFESTED WITH MICROALBUMINURIA		
UACR	Age	
<30	53.916	
30-300	56.285	
SEX RATIO OF HYPERTENSIVE PATIENTS MANIFESTED MICROALBUMINURIA		
UACR	Male	Female
<30	44.44	55.56
30-300	57.14	42.86

**Figure-10: Microalbuminuria is 28% prevalent among hypertensive patients.****Figure-11: Hypertensive patients having duration of HTN more than 10 years are at increased risk of renal disease.**




Figure-12: Mean age of hypertensive patients manifesting MAU is 56.295 yrs.




Figure-12: Percentage of microalbuminuric hypertensive males is high than females.

#### 4. RESULTS

The present study is a case study conducted in Dawadmi, College of Medicine, Dawadmi KSA. The study

comprises of 50 hypertensive subjects as study group, in which Serum Creatinine and Urinary Albumin Creatinine Ratio were estimated.

The study includes the patients with mean and standard deviation.

Variable	Male	Female
Age	$59 \pm 13.48$	$51 \pm 13.73$
Average BMI	$22.56 \pm 3.26$	$26.95 \pm 4.42$
Duration of HTN	$5.61 \pm 5.08$ yr	$4.4 \pm 6.23$ yr
Ser. Creat.	$1.03 \pm 0.23$	$0.83 \pm 0.28$
Urine Creat.	$0.69 \pm 0.20$	$0.68 \pm 0.27$
Urine Alb.	$37.36 \pm 43.81$	$26.94 \pm 36.61$
UACR	$51.29 \pm 56.72$	$40.73 \pm 55.84$

Maximum hypertensive patients belong to

Duration of HTN- less than 4 years

Age-40-50 years

BMI-20-26 Kg/m<sup>2</sup>

Mean serum creatinine-0.80-1.20mg/dl

Mean UACR-<30mg/g

Mean urine creatinine-0.60-0.90g/dl

Mean urine albumin-<40mg/dl

### The following observations were noted

#### 1. Correlation of Serum Creatinine, Urinary Albumin & UACR with Duration of Hypertension

Subjects were divided according to duration they are suffering from hypertension and their UACR was correlated with duration of hypertension. The study done by VK Sharma *et al.* Bhopal found a positive correlation of UACR with duration of hypertension. Our results supported the study we also found a positive correlation of UACR with duration of hypertension. Similarly serum creatinine and urine albumin were positively correlated with duration of the Hypertension.

#### 2. Correlation of Serum Creatinine, Urine Albumin and UACR with stage of HTN

Higher value of serum creatinine, urinary albumin and UACR was found in HTN-I than HTN-II.

#### 3. Prevalence of MAU in hypertensive patients

We observed UACR 30-300 mg/ gm in 28 % patients that is in the present study prevalence of MAU among hypertensives is 28%.

Prevalence's observed by different authors.

Roberto Bigazzi *et al.* (1988) 40%

Roberto Pontremoli *et al* (1997) 6.7%

S. Jalal *et al* (2007) 37.5%

Steven J Chadban(2003) 2.4%

T Konta *et al* (2006) 17.8%

#### 4. Prevalence of serum creatinine among hypertensive patients:

Serum creatinine exceeding 1.4 mg/dl was found in 10% hypertensive patients that are if it is taken as a measure for renal disease then only 10% hypertensive patients are showing renal dysfunctions. These 10% patients show higher values of ACR that means increase in serum creatinine is advanced stage of microalbuminuria.

#### Percentage of Microalbuminuric Hypertensive patients when assessed by spot UACR and Urinary Albumin alone

In our study we found that prevalence of MAU when assessed by spot UACR and urinary albumin is 28% and 22% respectively. The frequency of Urine Albumin and UACR is 78.57 % correlated.

Thus it is a better measure for routine diagnosis of renal dysfunctions. It will provide convenience and decreases; about the measuring urine creatinine values. Ulla Derhaschnig *et al.* (1985) also justify the use of albumin screening alone in place of ACR.

#### 5. DISCUSSION

##### HYPERTENSION AND THE KIDNEYS

The kidney can be considered as both culprit and victim in hypertension process.<sup>[62]</sup> The kidney responds rapidly to changes in blood pressure by alteration of renal hemodynamics and sodium excretion. These functions of

the kidney are reset in established HTN.<sup>[63]</sup> Deranged renal function contributes to the development of arterial HTN and of secondary vascular damage at the glomerulus and arteriolar level and accounts for the development of progressive nephrosclerosis. The most common alteration of renal function observed in humans from the early stages of essential HTN is the presence of renal vasoconstriction.<sup>[62]</sup>

MAU is commonly thought of as an important risk factor for identifying kidney disease. A number of studies strongly verifies the prevalence of MAU in HTN. MAU is associated with an increased risk for renal morbidity and mortality in patients with HTN.<sup>[64, 65, 66, 67, 68]</sup> Roberto bigazzi *et al*, 1988 (5) studies UAE in group of 123 patients with essential HTN and 40% of patients manifested a UAE exceeding 30 mg/24 hrs. Damsgaard *et al*, 1990 reported a higher prevalence of MAU in a group of 216 elderly hypertensive patients.<sup>[70]</sup>

Agewell *et al* (1993) reported an 23% prevalence of MAU in a population of hypertensive patients who were selected at high risk for cardiovascular disease.<sup>[71]</sup> Summerson *et al*, 1995 studies 190 patients with essential HTN and prevalence of MAU was found 32% in blacks and 14% in whites<sup>[69]</sup> Roberto pontrrimoli *et al*, 1997 studies prevalence of MAU in HTN and it's clinical correlates. Out of 1787 patients prevalence of MAU was 6.7%. (2). S. Jalal *et al* (2001) studied 288 patients with HTN among which 37.5 manifested MAU. Steven J Chadban *et al*, 2003 found proteinuria in 2.4% cases which was increasing with age.<sup>[8]</sup> 25-44 years 0.8%, 65 years 6.6%.

Hens Henrick Parving(2004) found 22% prevalence of MAU in hypertensive patients with DM-II. (72). T Konta *et al* (2006) examined the prevalence of MAU and it's associated risk factors in Japan. A total of 2321 subjects were examined, the prevalence of MAU was 17.8%.<sup>[73]</sup>

V.K. Sharma *et al* studied 50 patients with essential HTN and found 24% prevalence of MAU. The prevalence was increasing as the duration of HTN increases.<sup>[18]</sup>

#### DIAGNOSIS OF RENAL DAMAGE IN HTN

Routine blood and urine analysis is done commonly to detect renal damage. The National Kidney Foundation recommends, three simple tests to screen for kidney disease.<sup>[20,9]</sup> A blood pressure measurement. A spot check for protein or albumin in urine.

Calculation of GFR based on a serum creatinine measurement. Blood urea nitrogen provides additional information.

#### 6. SUMMARY

The present study entitled "Renal Damage Assessment With Reference To Microalbuminuria In Hypertensive Patients" is done to assess prevalence of microalbuminuria among hypertension subjects and it's

utility over serum creatinine assessment. Serum creatinine. Prevalence of microalbuminuria was compared with more than normal serum creatinine levels among hypertensive patients.

The study group comprises of 50 hypertensive patients. The pointwise conclusion of result is as follows.

1. Microalbuminuria is 28% prevalent among hypertensive patients.
2. Hypertensive patients as having more than normal serum creatinine level have high value of UACR thus we can say that increment in serum creatinine level is advance stage of renal damage.
3. Out of 14 patients which are considered microalbuminuric on the basis of UACR value, 11 have high urine albumin also thus it can be diagnosed for microalbuminuria.
4. Hypertensive males are more prone to microalbuminuria than hypertensive females.
5. Maximum hypertensive patients belongs to duration less than 4 years Serum creatinine is increasing with Age while urine albumin and UACR shows no correlation with duration of HTN
6. Maximum hypertensive patients belong to age group 40-50 yrs then in age of 60-70 yrs.
7. Serum creatinine urine albumin and UACR shows no correlation with age.
8. Serum creatinine is decreasing with increment in non-vegetarian diet while UACR and Urine Albumin can not be correlated
9. Type I and type II hypertension is equally prevalent among hypertensive patients
10. Serum creatinine, urine albumin and UACR is found to be high in type I than in type II HTN.
11. Serum creatinine is decreasing with increment in non-vegetarian diet while UACR and Urine Albumin can not be correlated.
12. Serum creatinine, urine albumin and UACR is found to be high in male than in female hypertensive patients.
13. Maximum hypertensive patients have serum creatinine value 0.80-1.20 mg/dl
14. Maximum hypertensive patients have normoalbuminuria
15. Maximum hypertensive patients have urine creatinine value in the range 0.60-0.90 g/dl
16. Maximum hypertensive patients have urine albumin <40 mg/dl
17. Patients having high serum creatinine value have high value of UACR also.

## 7. REFERENCES

1. Soma Panda; "Orissa Review HTN; Advanced study centre in psychology", Utkal University, 2006.
2. Tirrota A, Ruella N, Tomolillo C, Castello C, Grillo G, Scchi G, Deferrari G. (1997), Prevalance and clinical correlates of MAU in essential hypertension: The magical study. MAU: A Geneva investigation on complications. HTN, 30: 1135-1143.
3. Datey k.k, kumAr M, Goyal B.K. (1982), Recent advances in the management of HTN. Indian Heart Journal, 34: 349-355.
4. Jalal S, FA Sofi, MS Alai, MA Siddiqui, MA Bhatt, K A Khan, V M Jan, NA Lone, H A Rather. (2001), Prevalence of Microalbuminuria in essential Hypertensive: A study of patients with mild to moderate Hypertension Indian Journal of Nephrology, 11: 6-11.
5. Roberto Bigazzi, Stefano Bianchi, Vito M Campese Giorgio Baldori, (1992), Prevalence of MAU in a large population of patients with mild to moderate essential Hypertension. Nephron, 61: 94-97.
6. Kothiwale V A et al, Kle Society Hospital and Medical Research Center Belgaum, Significance of MAU in Essential Hypertension.
7. Valensi P, Assayag M, busby M, Paries J, Lormeau B, Attali JR. Department of Endocrinology Diabetology Nutrition. Jean Verdier Hospital, Paris, Nord University Bondy, France. MAU in Obese patients with or without HTN.
8. Steven J. Chadban, Esther M Briganti et al, (2003), Prevalence of kidney damage in Australian Adults kidney study, The Aus Diab Kidney study, J Am Soc Nephrol, 14(S): 131-138.
9. <http://www.webhealthcentre.com/diseaseconditions/kidney>. Thursday, Feb 18, 2010; 12: 42:56 pm.
10. Dr. RVSN Sharma, MD, Consultant Physician, Bhopal.
11. Parving H.H, Jenson H. E, Mogensen C.E, Evrin P.E. (1974), Increased urinary albumin excretion in benign essential HTN. Lanset, 1: 231-237.
12. Losito A, Fortunati F, Zampi I, Del Favero A. (1988), Impaired functional reserve and albuminuria in essential HTN. Br Med J, 1: 1562-64.
13. Giacconi S, Levanti C, Fommei E, Innocenti F et al. (1989), MAU and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild HTN. Am J Hypertens, 2: 259-61.
14. [http://www.medicine.net.com/creatinine\\_blood\\_test/article](http://www.medicine.net.com/creatinine_blood_test/article). March 13, 2010. Author- Siamak nabili, MD, MPH.
15. Lewin A, Blaufox D, Castle H, et al. (1985), Apparent prevalence of Curable Hypertension in the Hypertension detection and follow up programme. Arch Intern Med, 145: 424-27.
16. Samuelsson O, et al. (1985), Predictors of Cardiovascular morbidity in treated Hypertension. Results from the primary preventive trial in Goteborg. Sweden J Hyperten, 3: 167-76.
17. Kannel WB, Stemfer MJ, Castelli WB, Verter J, (1984), The prognostic significance of proteinuria: The Framingham study Am Heart J, 108: 1347-52.
18. V K Sharma, T N Dubey, R K Jain, M Gupta, N Rao, S Chittawar, R Nayak (GMC) Study of prevalence of MAU in Essential Hypertension and its correction with severity and duration.
19. Ulla Dergaschnig; Harald kittler, Christian woisetschlag, Andreas Burr, Harald Herckness,

Micheal M Hirschl; (2002), Microalbumin measurement alone or calculation of the ACR for the screening of hypertensive patients; *Nephrol Dial transplant*, 17: 81-85.

20. The kidneys and how they work? National Institute of health (U.S.), publication no. 09-3195; February 2009.
21. Guyton & Hall, Textbook of medical physiology, Tenth Edition (pg no. 280-281)
22. Clinical Chemistry: theory, analysis and correlation/ Lawrence A Kaplan, Amadeo J Pesce- 4th Edition (pg no. 479-480).
23. Essentials of Medical Physiology; 4th Edition K sembulingam.
24. HTN- Wikipedia, the free encyclopedia. <http://en.wikipedia.org/wiki/hypertension>.
25. Oparil S, Zaman MA, Calhoun DA, (November 2003). "Pathogenesis of HTN" *Ann Intern Med*, 139(9): 761-67.
26. HTN: eMedicine Nephrology <http://emedicine.medspace.com/article/241381-overview>.
27. Chonobanian AV, Bakris GS, Black HR et al (Dec 2003),"Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure" <http://hyper.ahajournals.org/cgi/content/full/42/6/1206>.
28. Hypertension, 2006; 48: 201, American heart association, Inc. Editorial commentaries, Potassium Depletion and Diastolic dysfunction David B Young, Deptt of physiology and Biophysics. University of Mississippi, Medical centre.
29. Lackland DT, Egan BM (Aug 2007), "Dietary salt restriction and blood pressure in clinical trials" *Curr. Hypertens. Rep.*, 9(4): 314-319, doi:10.1007/s11906-0078-0057-8.
30. Kosugi T, Nakagava T, Kamath D, Johnson RJ. (Feb 2009). "Serum uric acid and hypertension: as age related relationship" *J Hum Hypertens*, 23(2): 75-76.
31. Loscalzo, Joseph; Fauci, Anthony S, Braunfald, Eugene, Dennis L, kasper, Hauser, Stephen L, Longo, Dan L. (2008), "Harrison's Principle of internal Medicine ". MC Graw Hill Medical ISBN 0-07-147691-1.
32. Inaba S, Iwai M, Honuchi M. (Aug 2008), "Role of RAS in Prehypertension" *J Nippon Rinsho*, 6618: 1503-8.
33. Sorof J, Daniel S. (Oct 2002), "Obesity HTN in Children: a problem of epidemic proportions" *HTN*, 40(4): 441-7.
34. Uchiyama H. (Aug 2008), Mild HTN in children: *Nippon rinsho*, 66(8): 1477-80.
35. Singer DR, Kite A. (June 2008), "Management of HTN in Peripheral arterial disease does the choice of drug matter?" *European journal of vascular and endovascular surgery*, 35(6): 701-8 doi: 10.1016/jejvs.2008.01.007.
36. Novo S, Lunetta M, Evola S, Novo G. (Jun 2009), "Role of ARB's in the blood HTN therapy and prevention of cardiovascular events" *Current drug targets*, 10(1): 20-5- doi:10.2174/138945009787122897.
37. White WB. (May 2009), "Defining the problem of treating the patient with HTN and arthritis pain" *The Am J of Med*, 122: S3-9. doi: 10.2459/ JCM. 0B013e32831da941.
38. Pendrinelli R, Dell'omo G, Talini E, Canale ML, Di Bello V. (Feb 2009), "Systemic HTN and the right sided cardiovascular system: a review of the available evidence" *Journal of Cardiovascular medicine (hagestown MD)* 10(2): 115-21. doi: 10.2459.
39. Rodriguez NA, Zurutuza A. (2008), "Ophthalmic logical manifestations of arterial HTN " *Anales Del Sistema Sanitario De Navarra* 1; 13-22.
40. Pitt's SR, Adams RP. (Feb 1998), "Emergency deptt HTN and regression to the mean" *Annals of Emergency Medicine*, 31(2): 214-18.
41. Chiang WK, Jamshahi B. (Nov 1998), "Asymptomatic HTN in the ED" *The American Journal of Emergency Medicine*, 16(7): 701-4.
42. Decker WW, Godwin SA, Hess TP, Lenamond CC, Jagoda AS. (May 2007), "Clinical policy, critical issues in the evaluation and management of adult patients with asymptomatic" *Clinics in geriatric medicine*, 23(2): 363-70.
43. Zeller KR, Von Kunkel L, Matthews C. (October 1998), "Rapid reduction of severe asymptomatic HTN. A Prospective controlled trial" *Archives of Internal Medicine*, 149(10): 2186-9.
44. Papadakis, Maxine A, McPhee, Stephen J. (2008), *Current Medical Diagnosis and treatment 2009*. (Mc Graw hill ISBN 0-07 159124-9).
45. HTN: e Medicine pediatrics: "Cardiac Disease and critical care medicine" <http://emedicine.com/article/889877-overview> 2009-06-16.
46. Ruilope, Luis M, "Renal damage in HTN" *European journal of cardiovascular prevention and rehabilitation*. Feb 1995; 2.
47. AEG Raine, "HTN and the Kidney" April 2006. The Magazine, 5.
48. Hans L et al "MAU is also common in non diabetic, non hypertensive population and an independent indicator of cardiovascular risk factors and cardiovascular morbidity." *J Intern Med*, 2001; 249: 519-526.
49. Cerasola G ET AL "MAU Renal Rysfunction and Cardiovascular Complication in essential HTN". *J Hypertens* 1996; 14: 915-920.
50. Jensen J S, et al. (1997); "MAU and it's relation to CVD and Risk factors". *J Hum Hypertens*, 11: 727-732.
51. Jager A et al. (1999), "MAU and Peripheral arterial disease are independent predictors of cardiovascular disorders and all cause mortality, especially among hypertensive subjects" *Arterioscler Thromb Vasc Biol*, 19: 617-624.

52. Mattock MB et al. (1992), "prospective study of MAU as predictor of mortality in NIDDM". *Diabetes*, 41: 736-41.
53. Jarett RJ et al. (1984); "MAU predicts mortality in non insulin dependent diabetes". *Diabet Med*, 1: 17-19.
54. Summerson J.H. et al. (1995), Racial differences in the prevalence of MAU in Hypertension. *Am J Kidney Dis*, 26: 377-579.
55. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. (1990), Microalbuminuria as a predictor of increased mortality in elderly people. *Br Med J*, 300: 297-300.
56. Agewall S, person B, Samuelsson O, Ljungman S, Herlite H, Fagerberg B. (1993), Microalbuminuria in treated Hypertensive men at high risk of diseases. *J Hyperten*, 11: 461-469.
57. Hans Henrik Parving et al. (2004), Prevalence of MAU, arterial Hypertension, Retinopathy and neuropathy in patients with Imulin dependent diabetes.
58. T Konta et al. (2006), Prevalence and risk factor analysis of MAU in Japenese general population: The takahata study kidney International, 70: 751-756.
59. UACR: National Kidney Disease Education Programme. US deptt of health and Human Services. NIH Publication number.086286; May 2008.
60. [http://www.medicinenet.com/creatinine\\_blood\\_test/article.htm](http://www.medicinenet.com/creatinine_blood_test/article.htm); March 13 2010.
61. E.A. Medcalf, D J Newmann, E G Gorman, C D Price. (1990), Rapid, robust method for measuring low concentration of albumin in urine clin chem, 36/3; 446-449.
62. Jaffee's alkaline picrate method; (1886). *Analytical Chemistry, Theory and practice*, author- R.M. Verma; Third edition, 513-514.
63. Bcheraoui CB: Hypertension and Its Associated Risk Factors in the Kingdom of Saudi Arabia, 2013; A National Survey.